Zhejiang Pharma’s Loss May Be Amneal’s Gain As Trump’s Pharma Tariffs Approach May 16, 2018 President Trump’s aims to cut American healthcare costs face a hurdle from trade policy, with duties proposed on Chinese exports of pharmaceuticals as a result of the section 301 review. Chinese suppliers, led by Zhejiang Pharma, have had little success in the U.S., with shipments of just $405... Read more →
Indian Drug Trade Cure Is Also Its Illness As China Talks Continue March 26, 2018 Trade negotiations between the Indian and Chinese governments will likely include pharmaceutical market access. The Indian government has a list of 250 products it wants approved, and may need to give up “Make In India” tariffs to do so. Indian exports managed to grow 12% on a year earlier in ... Read more →
Trump’s Drug Order May Come as Oncology Bucks Falling Pharma Costs June 28, 2017 President Donald Trump may shortly issue an Executive Order calling for the USTR to carry out a “comprehensive review” of drug purchasing internationally. That could feed into the administration’s aims to cut healthcare costs. Panjiva data shows average costs per unit for imported pharmaceutic... Read more →
Executive Order May Prove Double-Edged Scalpel for Generic Pharma Producers June 16, 2017 A new Executive Order from President Trump will seek to control drug pricing. That may pull the generic drugmakers that export to the U.S. in two directions. A desire for cheaper drugs will help them, while new rules on intellectual property may make the formulation of new generic drugs more d... Read more →
Drug Misuse Rule Changes Visible in AC Trade Data December 16, 2016 Yet, within the class, imports of gabapentin (generic Neurontin) dropped 18%. This may be linked to new reporting requirements relating to misuse of the drug as a painkiller. That change may have driven a switch to generic versions of GSK’s Lamotrigine and UCB’s Keppra which both reached recor... Read more →
中文
China
